ข่าวประชาสัมพันธ์ Actinic Keratosis+Ingenol Mebutate

Article Published in JAMA Dermatology Shows Long-term Effectiveness of Ingenol Mebutate in Treating Actinic Keratosis

Two-three day treatment provides clinically relevant, sustained clearance of AK after 12 months An analysis of long-term clearance rates of actinic keratosis (AK) lesions after treatment with ingenol mebutate (Picato(R)) gel is today published in the Journal of the American Medical Association (JAMA) Dermatology,[1] formerly known as the Archives of Dermatology. (Photo: http://photos.prnewswire.com/prnh/20130221/595427 ) Previously, the pooled results of the four phase III trials of ingenol

21 มีนาคม 2556 07:32 น.

Four Phase 3 Efficacy and Safety Studies of Ingenol Mebutate, an Investigational Treatment for Actinic Keratosis, Presented at World Congress of Dermatology

- Ingenol Mebutate is an Investigational Two-to-Three Day Topical Treatment for Precancerous Skin Disease Clinical data from four Phase 3... มิ.ย. 54

New Data Presented at WCCS Confirm High Long-term Efficacy of Picato(R) in Patients with Actinic Keratosis

Not for US media The digital press release with multimedia content can be accessed here: http://www.multivu.com/players/uk/7276254-WCCS-Picato-actinickeratosis New data from the international... ก.ย. 57

Picato(R) Gel Receives EU Marketing Authorisation for Treatment of Actinic Keratosis

Today LEO Pharma announced that the European Commission (EC) has granted marketing authorisation for Picato(R) (ingenol mebutate) gel as a treatment for actinic keratosis in the European Union (EU). Picato(R) gel is... พ.ย. 55